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ABSTRACT 
Significant research in tissue engineering has been devoted to the replication of cartilage by 
developing suitable scaffolds. The approach of Ren et al was to develop an injectable Hyaluronic acid-
tyramine hydrogel. HA-tyr hydrogels can be crosslinked by adding hydrogen-peroxide (H2O2) and the 
enzyme horse-radish peroxidase (HRP). However, the reaction is almost instantaneous and temporal 
control is difficult. By separating HRP from HA-Tyr and H2O2, the mixture is liquid. Hence, the main 
goal of this project was to develop a thermoresponsive system for HRP delivery aiming to trigger and 
control HA-Tyr crosslinking reaction.  
Most of this study was inspired from the Ren et al (2015) research. However, two types of 
themoresponsive liposomes were formulated within this study, having a different composition as 
well as different methods of preparation. Both types of liposomes were formulated and their release 
properties were investigated. 
Ren et al. (2015), developed a binary mixture of thermolabile synthetic phospholipids. In their 
research, they have successfully encapsulated the enzyme HRP but the process was difficult to 
reproduce. Multiple steps were shown within this project for ameliorating the sensitive processing. 
The second type of liposome was formulated with artificial synthetic phospholipids, synthesized by 
Professor Zumbühl and his team at the University of Fribourg. These formulations were shown to be 
more user-friendly and could be manipulated easily. 
  
ii 
 
ACKNOWLEDGEMENTS 
First of all, I would like thank Prof. Lee Ann Laurent-Applegate, Prof. Dominique Pioletti and Prof. 
Harm Anton-Klok, who gave me the opportunity to accomplish this master project. Their close 
collaboration and support was really helpful throughout this study. 
I would also like to express my gratitude to all the members of the Laboratory of Biomechanical 
Orthopedics (LBO) for their kindness, sociability and team spirit. A special thanks to my supervisor, 
Jens Antons, who gave me tremendous support and encouragement during the project and to Sandra 
Jaccoud for her useful hints and technical support. 
Finally, I would like to acknowledge my gratitude to Professor Andreas Zumbühl and his team from 
the University of Fribourg for their kindness and their valuable scientific support in this project. I 
particularly thank Radu Tanasescu for his help, guidance and detailed chemical explanations.  
  
iii 
 
CONTENT 
ABSTRACT ......................................................................................................................................................... I 
ACKNOWLEDGEMENTS .................................................................................................................................... II 
CONTENT ......................................................................................................................................................... III 
INTRODUCTION ................................................................................................................................................ 1 
1.1 CARTILAGE ................................................................................................................................................ 1 
1.2 HYALURONIC ACID-TYRAMINE HYDROGEL ........................................................................................................ 2 
1.3 LIPOSOMES ............................................................................................................................................... 4 
1.4 COMPOSITION OF LIPOSOMES ....................................................................................................................... 4 
1.5 CLASSIFICATION OF LIPOSOMES...................................................................................................................... 7 
1.6 LIPOSOME PREPARATION METHODS ................................................................................................................ 7 
1.7 LIPOSOME SIZE’S CHARACTERIZATION.............................................................................................................. 9 
EXPERIMENTAL DESCRIPTION ........................................................................................................................ 10 
2.1 REN ET AL. EXPERIMENT ............................................................................................................................. 10 
2.2 TANASESCU ET AL. EXPERIMENTAL APPROACH ................................................................................................. 11 
MATERIALS AND METHODS ........................................................................................................................... 12 
3.1 MATERIALS ............................................................................................................................................. 12 
3.2 LIPOSOME FORMULATION .......................................................................................................................... 12 
3.3 LIPOSOME’S SIZE CHARACTERIZATION............................................................................................................ 13 
3.4 RELEASE MEASUREMENT ............................................................................................................................ 13 
RESULTS & DISCUSSION ................................................................................................................................. 14 
4.1 FIRST RESULT ........................................................................................................................................... 14 
4.2 COMPOSITION OPTIMIZATION ..................................................................................................................... 16 
4.3 RELEASE METHOD OPTIMIZATION ................................................................................................................. 16 
4.4 LIPOSOME FORMULATION OPTIMIZATION ...................................................................................................... 16 
4.5 SECOND RESULTS ...................................................................................................................................... 18 
4.6 RADU ET AL. ENCAPSULATION ...................................................................................................................... 19 
4.7 LAST EXPERIMENT ..................................................................................................................................... 21 
4.8 SUMMERY ............................................................................................................................................... 22 
PERSPECTIVE .................................................................................................................................................. 24 
REFERENCES ................................................................................................................................................... 27 
ANNEX ............................................................................................................................................................. A 
 
 
1 
 
INTRODUCTION 
 
1.1 Cartilage 
Currently, articular deficiencies and injuries (age-related, sport…) are increasingly observed. Due to 
the limited healing capacity of cartilage, this can lead to functional limitation or, if left untreated, to 
complete cartilage loss.1 Thus, the patient’s life quality can be greatly affected. Hence, it is important 
to develop new cartilage repair strategies. Currently, new techniques such as tissue engineering 
investigate long term articular cartilage repair that can withstand high mechanical loading.2 
Tissue engineering or regenerative medicine tries to reproduce the biomechanical and biochemical 
characteristic of the native tissue. Even though cartilage tissue is avascular, aneural and alymphatic, 
it has a complex structure.3  Articular cartilage is mainly composed of water, accounting for 70-80% 
of its weight, and it contains structural proteins. The cells, commonly called chondrocytes, are 
embedded within the dense extracellular matrix (ECM) mainly made of collagen and proteoglycans. It 
is the collagen and the proteoglycans that provide the porous structure of cartilage and they also 
ensure most of the mechanical properties of the joint.  
 
Figure 1: (A) Knee joint anatomy4 (B) A section of cartilage’s structure showing chondrocytes embedded within the 
extracellular matrix (ECM). The fibrous structure of ECM is given by the collagen and the proteoglycans.5 
Since several years, significant research in tissue engineering has been devoted to the replication of 
cartilage by developing suitable scaffolds6,7; a support that must act as a temporary ECM by providing  
mechanical support and bioactivity. Several properties including biocompatibility, bioresorbability,  
promoting cell migration and tissue growth are required8. Currently, several limitations remain in the 
development of an appropriate scaffold for tissue engineering. For example, invasive surgery is often 
required which involves risk of infection or failure to heal. Secondly, it is difficult to perfectly mold a 
material into a defect site1.  
In order to address these issues above, a possible approach is to develop injectable scaffolds9. The 
method proposed by Ren et al. was based on the injection of a liquid hydrogel called hyaluronic acid-
tyramine, that can crosslink in the defect site in response to a stimulus10. 
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1.2 Hyaluronic acid-tyramine hydrogel 
Hyaluronic acid-tyramine (HA-Tyr) hydrogel can be synthetized by crosslinking conjugated tyramine 
hyaluronan (HA-Tyr) in the presence of hydrogen-peroxide (H2O2) and the enzyme horse-radish 
peroxidase (HRP).  
 
Figure 2: Crosslinking reactionof biodegradable HA-Tyr hydrogel11. 
HA-Tyr is a hydrogel with a covalently bound network. The crosslinking reaction occurs by an 
oxidative coupling of the phenol using hydrogen peroxide (H2O2) and a peroxide. The enzyme HRP is 
mainly used as an intermediate to oxidate the phenol groups, which will be described in more detail 
in this section11. The phenol hyaluronan tyramine derivative is a biocompatible and biodegradable 
polysaccharide and  it is a major constituent of the extracellular matrix of the joint 12. It was also 
shown that this hydrogel is adhesive to cartilage, hence it favors implantation4. In sum, HA-Tyr 
hydrogel seems very promising for the development of a cartilage tissue engineering scaffold. 
The complete schematic of the reaction is illustrated below. The crosslinking of phenols by HRP 
involves two successive steps; first, HRP is oxidized by H2O2 to form an intermediate [HRP(I)], which 
then oxidizes the phenol (S). Finally two oxidized phenols (R-) crosslink to form a covalent network12.  
(1)  𝐻𝑅𝑃 + 𝐻2𝑂2  
𝑘𝑎
→  𝐻𝑅𝑃(𝐼) + 𝐻2𝑂 
(2)  𝐻𝑅𝑃(𝐼) + 𝑆 
𝑘𝑏
→  𝐻𝑅𝑃(𝐼𝐼) + 𝑅− 
(3) 𝐻𝑅𝑃(𝐼𝐼) + 𝑆 
𝑘𝑐
→  𝐻𝑅𝑃 + 𝑅− +𝐻2𝑂 
(4)  2𝑅−  
𝐾𝑑
→ 𝑅 − 𝑅 
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HA-Tyr hydrogel can provide a wide range of applications of injectable hydrogels, such as tissue 
regeneration or drug delivery. In order to produce a suitable scaffold, it needs to have structural 
similarities such as porosity, shape or surface morphology to reproduce as close as possible the 
mechanical and biological properties of the native tissue13. 
The crosslinking density (mechanical strength) of this hydrogel is solely affected by the concentration 
of H2O211. It was shown that the crosslinking density directly affects the biodegradability of the gel 
which is essential since a scaffold should preferably be absorbed by the surrounding tissues. A 
second important factor for the development of an injectable scaffold is the gelation rate. Indeed, for 
drug delivery systems or micro-fissure tissue regeneration, hydrogels should rapidly form after 
injection, otherwise, uncontrolled diffusion of the gel, or contamination of surrounding tissue with 
the drug molecules might occur. The gelation rate of HA-Tyr hydrogel is influenced by the amount of 
HRP and the gelation time ranges from 1 second to 20 minutes11. In fact, the criteria for an injectable 
hydrogel would be that during manipulation the hydrogel remains in a liquid form and when it is 
injected into the defect site, the hydrogel should form and consolidate as rapidly as possible.  
The solution proposed by Ren et al. to control the gelation rate is to encapsulate HRP into 
thermoresponsive liposomes: by separating HRP from HA-Tyr and H2O2 at RT, the mixture would 
remain liquid10. Upon injection into the defect site and exposure to body temperature, the 
microcapsules would release HRP, resulting in the subsequent reaction (fig. 3) and the formation of a 
hydrogel scaffold. 
 
Figure 3: Model of an injectable HA-Tyr hydrogel by encapsulation HRP into thermoresponsive liposomes 
Thermoresponsive liposomes are vesicles that are sensitive to temperature.  Choosing a specific 
liposomal composition enables the release of a cargo at a specific temperature. The difference 
between room temperature (25°C) and body temperature (37°C) is not negligible, hence very 
interesting to discharge drugs or substances into a specific body site by means of thermoresponsive 
liposomes. The next chapters describe in detail how this phenomenon can occur.  
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1.3 Liposomes  
Liposomes are closed spherical vesicles composed of one or more phospholipid bilayers14. The major 
components of liposomes are phospholipids and cholesterol. It is the chemical properties of these 
lipids that control the behavior of the liposome. The amphiphilic character of phospholipids is due to 
their hydrophilic polar head and hydrophobic apolar tail. Thermodynamically,  the combination of 
these lipids into a membrane is favored in the presence of water15. The polar end is associated with 
water and the apolar tails are in the middle of the membrane (Fig. 4). The spherical structure is 
spontaneously formed as it has been thermodynamically proven that the free energy of the system is 
lower in a spherical geometry than in planar bilayer16. 
 
 
Figure 4: Structure and composition of liposomes14 
The structure of liposomes, forming an inner and an outer aqueous space, enable the encapsulation 
of both hydrophobic and hydrophilic material. The center of the membrane provides a place for non-
polar substances and the lumen of the liposome provides a place for polar substances. Presently, 
liposomes are extensively used as drug carriers for numerous molecules in cosmetic and 
pharmaceutical industries17. This type of delivery system has the advantage to entrap unstable 
compounds, shield their functionality and deliver the drug at a targeted place. Several other 
advantages using liposomes are their biocompatibility, biodegradability and non-toxicity18.  
The lipid bilayer offers a basic barrier for the diffusion of entrapped material. Permeability of the 
membrane is affected by (1) lipid composition (2) surface charge (3) physical properties of the 
medium such as pH and temperature, and (4) shear stress18. For instance, unsaturated phospholipids 
(found in natural sources such as egg or soybeans) give much more permeable and less stable 
bilayers then saturated phospholipids with long acyl chains (e.g. dipalmitoylphosphatidylcholine, 
DMPC)18. 
 
1.4 Composition of liposomes 
As mentioned above liposomes are mainly composed of phospholipids.  
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The structure of a phospholipid is composed of two major portions: a hydrophilic head and a 
hydrophobic tail. All phospholipids are composed of a glycerol backbone, a phosphate group as well 
as two hydrocarbon chains as shown in the figure below. 
 
Figure 5: General structure of a phospholipid19 
The hydrophilic head can either be neutral, negatively or positively charged. To further modify the 
properties of liposomes it is common to add a sterol or an ionic substance. The addition of an ionic 
substance gives a charge to the membrane that can, for instance, prevent vesicle aggregation due to 
repulsion forces or provide a higher hydrophilic loading efficiency20. 
The length and the degree of saturation of the two hydrocarbon chains affect the permeability of the 
membrane. In brief, the higher the number of carbon atoms, the longer is the chain and the longer 
the chain, the smaller is the lateral expansion between the two chains (due to greater hydrophobic 
interactions)21. Hence, permeability of the membrane is increased with the length of the chain. 
Another parameter that can affect the chain length is the configuration. There are two possible 
configurations, cis or trans. In trans configuration, the chain is fully extended, whereas in cis 
configuration the chain is bended, and thus reduces its size. The figures below show the difference 
between trans and cis conformations.  
Saturated phospholipid in trans conformation Unsaturated phospholipid in cis conformation 
 
 
 
 
 
 
 
 
Usually, an unsaturated chain has a cis conformation that induces lower possibility for hydrophobic 
interactions and lateral expansion between the two chains. This phenomenon implies greater degree 
of freedom. 
To summarize, saturated phospholipids with long chains (such as dipalmitoylphosphatidylcholine, 
DPPC) form a rigid and rather impermeable bilayer, whereas membranes composed of unsaturated 
lipids with short chains are much more permeable and less stable. 
Temperature is also a factor that can affect the permeability of the membrane. Indeed, each 
phospholipid has a specific phase transition temperature (Tc)22 (see annex A1). It is defined to be the 
temperature at which the lipid physical state converts from an ordered gel phase to a disordered 
liquid crystalline phase (see figure below). 
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Figure 6: Phase transition temperature (Tc) of phospholipids going from gel to fluid physical state23 
In the gel phase, lipid molecules are ordered and packed together forming a two-dimensional plane 
membrane. Upon heating, mobility of the lipids increases gradually. The energy given by the increase 
of temperature (in the form of heat) enables the carbon-carbon bonds to rapidly rotate around their 
axes forming different conformers21 (see annex A2). This phenomenon decreases the hydrophobic 
interaction between the chains. Therefore, it enables the lipids to move more freely within the plane. 
As a result at Tc the membrane becomes fully fluidized and is permeable. 
Tc depends on the hydrocarbon chain length, degree of saturation, charge and head group species 
(see Table in Annex A1). The use of phospholipids with higher phase transition temperatures 
generates bilayers, which are more stable and rigid. This decreases the possibility for premature 
leakage of encapsulated components. On the other hand, if the phase transition temperature of the 
selected phospholipid is too high, high temperature might denaturate the encapsulated cargo during 
the process of liposome formulation. Indeed, as will be explained later in this report, in order to 
formulate liposomes the medium temperature has to be higher than the phase transition 
temperature of the lipids within the mixture. 
In all, the molar percentage of phospholipids can vary between 55 and 100%22. The remaining 
percentage is composed of components that can be added to the formulation in order to impart 
specific property to the final vesicles. For instance, to stabilize the bilayer from leaky properties 
additional sterol can be employed. As shown on Figure 7, cholesterol is one sterol that is widely used 
for this purpose. 
 
 
 
 
 
 
 
Figure 7: Cholesterol molecules embedded into a phospholipidic bilayer24 
The small and rigid structure enables it to lodge between the phospholipid’s apolar chains, which in 
turn limits their degree of freedom.  Overall, cholesterol increases the rigidity of the phospholipid 
bilayer. Most studies have shown that in order to prepare stable and controlled drug release 
vehicles, a molar composition of 70% of lipids and 30% of cholesterol is required25.  
 
 
7 
 
1.5 Classification of liposomes 
Generally, liposomes are classified by two factors: their size and their number of bilayers21. Both of 
these parameters influence the encapsulation efficiency of the liposomes. 
Effective and stable encapsulation depends on the physico-chemical properties of the substance that 
should be encapsulated (size, charge, hydrophobicity), but also on liposome features (size, type, 
composition and concentration of lipids)22. As mentioned before, both hydrophilic and lipophilic 
molecules can be encapsulated in the lumen of the liposome or within the bilayer, respectively. 
There are two ways to encapsulate a substance: one called the passive way, where the encapsulation 
occurs during liposome preparation, and the second  the active way, where the cargo is introduced 
into preformed liposomes22. Depending on the liposome formulation method and the substance that 
should been capsulated, the active or passive way can be used and for a better understanding, 
liposomes have to be classified. 
Liposome size can vary from very small being several nanometers in size, to large vesicles with a few 
micrometers in diameter. Furthermore, they can have one or more bilayer membranes. They are 
typically classified into four main categories as can be seen in figure 8: 1) Small Unilamellar Vesicles 
(SUV), 2) Large Unilamellar Vesicles (LUV), 3) Multilamellar Vesicle (MLV) and 4) Multivesicular 
Vesicles (MVV).  
 
Figure 8: Classification of liposomes based on size and lamellarity18 
In unilamellar structure, the vesicle has a single phospholipid bilayer, whereas in multilamellar 
structure, the vesicles have an onion-like structure. In the case of Multivesicular Vesicles several 
unilamellar vesicles are formed inside of larger liposomes, forming a multilamellar structure of 
concentric phospholipid spheres. 
The encapsulation efficiency of liposomes increases with the size of the liposome and decreases with 
number of bilayers (for hydrophilic compounds only). Likewise, the larger the radius curvature, the 
weaker is the tension surface. Hence, optimum liposome encapsulation efficiency and stability is 
reached when the vesicles have a size between 80 and 100 nm22. 
 
1.6 Liposome preparation methods 
Although liposome formation can occur spontaneously when the lipids are transferred into an 
aqueous medium (thermodynamic equilibrium), it often requires supplementary steps. The 
preparation method has a great influence on the properties of the liposomes: size, shape, stability 
and drug loading efficiency.  
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Figure 9 depicts the four basics stages for the preparation of liposomes: 1) Dispersing the lipids into 
an organic solvent, 2) Forming a thin lipid film by evaporating the organic solvent, 3) Hydrating the 
lipid film and 4) Processing additional steps to get a homogeneous liposome formulation.  
 
Figure 9: General steps for liposome's formulation 
Regardless of the mixture of lipids (neutral or ionic), the dispersion step is always the same. The 
different lipids are first dissolved into an organic solvent, usually chloroform and/or methanol, to 
ensure a homogeneous mixture of lipids. The organic solvent is then removed to obtain a thin lipid 
film on the wall of the round bottom flask. Usually, evaporation is performed using a rotary 
evaporator connected to a vacuum pump. The round bottom flask can then be placed under vacuum 
overnight to ensure complete removal of residual solvent. The third hydration step, is performed by 
adding an aqueous solution. It is important to work at a temperature that is always higher than the 
phase transition temperature of the lipids in order to permit liposome formation. Encapsulation 
efficiency as well as the size of the liposomes (MLV) varies depending on the processing time and 
agitation. MLV, obtained by this method, can be homogenized by sonication or extrusion. 
In the sonication process,  ultrasound is used to break down the MLV into SUV (generally 20 to 50 
nm)22. A sonication bath or a probe tip sonicator can be used. Generally, probe tip sonication is 
mostly applied since the power is far higher than bath sonication. The only drawback is that the 
probe can contaminate the suspension with traces of metal which have to be eliminated by 
subsequent centrifugation. Sonication has to last until the formulation becomes clear and slightly 
opalescent at a temperature higher than the Tc. The cloudy effect is due to light dispersion on the 
remaining MLV. The encapsulation efficiency by the sonication process is very low. Furthermore, it is 
challenging to reproduce exactly the same sonication condition between each batch and the 
liposome’s size dispersion will differ batch dependently.  
A second method for the regulation of liposome suspension is by extrusion. This technique consists 
of forcing the liposomal suspension through a filter with a given pore diameter, in order to recover 
liposomes with a size near the pore diameter of the filter. The extrusion process also has to be 
performed at a temperature higher than the Tc. If the liposomal suspension passes through the filter 
more than 10 times it is possible to have LUV with an average diameter of 120 to 140 nm22. There are 
three advantages of extrusion: first the size of the liposomes is reproducible from one batch to 
another, second this method is very fast and third encapsulation efficiency can be higher than 30%22. 
Modern novel methods for liposome preparation are continuously developed26. There are several 
possibilities to formulate liposomes27, but the two methods that were used in this work are described 
below: 
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1. Freeze-drying method 
Pre-formed SUVs are frozen and then dried during a lyophilization process. The dried lipids, in the 
form of lyophilized powder, are then directly hydrated with the aqueous phase. During hydration, 
SUV membranes merge to form MLV with a high encapsulation volume. This method is generally 
used when a component is thermolabile and would be destroyed during the hydration or regulation 
step. 
2. Freeze-thaw method 
This method applies several freeze and thaw cycles on pre-formed SUVs. The fusion of SUVs with 
each other results in the formation of LUVs with high encapsulation efficiency (between 30-80%). 
This technique can also be used during the hydration of lipid films receiving LUVs directly instead of 
MLVs. 
1.7 Liposome size’s characterization 
In order to assess the quality of liposomes and to determine whether batches are reproducible from 
one another, the size of the vesicles can be measured. In the present study, the size determination of 
the liposome was performed using dynamic light scattering (DLS). 
Dynamic light scattering (DLS) is a well know technique to measure the size and the size distribution, 
more particularly in the sub-micron region of suspended particles. A laser emits through the solution 
and the Brownian motion caused by the vesicles in suspension causes laser light to be scattered at 
different intensities. As the Brownian motion and the intensities are related, using Stokes-Einstein 
relation, the size of the particles can be then determined. 
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Figure 10: Phase diagram constructed from initiation 
and completion temperatures of a binary mixture 
DPPC/DMPC.  (- -) represent the ideal phase diagram 
whereas (--) is an extrapolation of six measurements28. 
EXPERIMENTAL DESCRIPTION 
Thermoresponsive liposomes are vesicles which release their cargo in response to heating. Lipids 
undergo a specific phase transition temperature that changes the conformation of phospholipids 
going from a gel to a fluid phase, allowing the diffusion of material through the membrane. Hence, 
the liposome composition is determined in function of the target release temperature. 
 
2.1 Ren et al. experiment 
In summaryl, Ren et al. wanted to develop an injectable HA-Tyr hydrogel10. By encapsulating HRP into 
thermolabile liposomes, the HA-Tyr system would remain liquid at room temperature. Through 
exposure to body temperature, the components of the liposomes would undergo a gel to liquid 
phase transition resulting in the release of the cargo. Once HRP, HA-Tyr and H2O2 are brought 
together, the crosslinking reaction occurs almost spontaneously forming a biodegradable and 
biocompatible hydrogel. This injectable hydrogel seems very promising as it can perfectly mold 
defect sites. 
The composition of thermolabile liposomes has to be especially defined to trigger release at body 
temperature (37°C). Until today, there are no natural or synthetic phospholipids on the market that 
have a phase transition temperature precisely at 37°C (see table 1, annex A1). Thus, a mixture of 
different phospholipids has to be chosen. Ren et al. decided to take a combination of two different 
phospholipids: dipalmitoyl pholsphatidylcholine (DPPC) and dimyristoyl pholsphatidylcholine (DMPC). 
Both of them are neutral saturated phospholipids having 16 and 14 carbon atoms in the hydrocarbon 
chains, respectively. Their phase transition temperatures are: Tc (DPPC) = 41°C and Tc (DMPC) = 23°C. 
Mabrey and Sturtevant have investigated the phase 
transition temperature of a binary mixture 
DPPC/DMPC, by high sensitive differential scanning 
calorimetry28. The phase diagram was constructed by 
specifying (on the bottom line) the onset temperature 
and (on the upper line) the completion temperature. 
The straight line is an extrapolation of six DSC 
measurements, hence is the empirical phase transition 
temperature of DPPC/DMPC. In this case, figure 10 
depicts, that the phase transition temperature of the 
binary mixture does not behave ideally (where the 
dashed line is the ideal phase diagram). As first 
approximation, in order to have a system with a phase 
transition temperature of 37°C, the molar amount of 
DPPC has to be four times higher than the molar 
amount of DMPC according to Marbrey and 
Sturtevant binary phase diagram.  
Initially, the liposome preparation method proposed by Ren et al. was the freeze-dried method 
which is also called Dehydration-Rehydration Vesicle technique (DRV)10. As mentioned in the 
“liposome preparation methods” chapter, this method is based on controlled rehydration of 
preformed dehydrated vesicles.  
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2.2 Tanasescu et al. experimental approach 
Another batch of completely different thermoresponsive liposomes was formulated in the chemical 
laboratory of Professor Zumbühl at the University of Fribourg.  Indeed Prof. Zumbühl and his team 
have developed artificial phospholipids 1,3-diaminophospholipid, named Pad-PC-Pad29. They have 
noted that Pad-PC-Pad forms faceted large and giant unilamellar vesicles (Fig. 11 A).  The particularity 
of these faceted liposomes originates from the fact that hydrocarbon chains interdigitate (Fig. 11 B) 
with each other as a main factor for the stabilization of facets.  
 
Figure 11: A) Faceted geometry of Pad-PC-Pad30. B) Pad-PC-Pa bilayer29. 
The faceted Pad-PC-Pad liposome has the specificity to be mechanosensitive and thermosensitive at 
the same time. According to the research conducted by Tanasescu et al. 30, the phase transition 
temperature of Pad-PC-Pad is around 37°C (as depicted in the figure below). This property makes it 
interesting for the development of thermoresponive liposomes that can release a cargo at body 
temperature. The figure below shows the differential scanning calorimetry (DSC) of Pad-PC-Pad 
liposomes containing different amounts of cholesterol.   
 
Figure 12: Differential Scanning Calorimetry scans of a mixture of Pad-PC-Pad and cholesterol30. 
As the amount of cholesterol increases, the phase transition temperature of the liposomes 
decreases. Hence, pure Pad-PC-Pad liposomes can lead to a discharge of material at a temperature of 
37°C. 
The preparation method of Pad-PC-Pad liposomes is produced by going through the four basics steps 
of liposome formulation explained in the ‘’liposome’s preparation methods’’. Freeze-thaw cycles 
were performed to obtain LUVs during the hydration step. In the next chapter (or in Tanascescu et 
al., 2016) the detailed method for faceted Pad-PC-Pad liposome formulation is elucidated.   
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MATERIALS AND METHODS 
3.1 Materials 
 Phosphate Buffered Saline, PBS, pH 7.4, 1X (Gibco, Life Technologies, USA) 
 1,2-dimyristoyl-syn-glycero-3-phosphocholine, DMPC (Avanti Polar Lipids INC., USA) 
 1,2-dipalmitoyl-sin-glycero-3-phosphocholine, DPPC (Avanti Polar Lipids INC., USA) 
 Cholesterol, grade ≥ 99% (Sigma Aldrich, USA) 
 1,3-diaminophospholipid, Pad-PC-Pad (Fribourg university, CH) 
 Peroxidase from horseradish, type I, RZ: 146 units /mg Solid (Sigma Aldrich, USA) 
 Carboxyfluoroscein, (Sigma Aldrich, CH) 
 Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Labeling & Detection, Life 
Technologies, USA) 
3.2 Liposome Formulation 
Method 1 
Given ratio of DPPC, DMPC and cholesterol (unless other mentioned: 80.9 mg, 25.2 mg and 29.4 mg 
respectively) were dissolved in 5 mL chloroform in a 50 mL round-bottom flask. The organic solvent 
was evaporated with a rotary evaporator (Büchi rotavapor R-205) at 50°C (Büchi heating bath B-490) 
under reduced pressure (Büchi vacuum Controller V-800). The lipid film was hydrated with 5 mL 
phosphate-buffered saline (PBS 1X) during 30 minutes in a 50°C water bath with intermittent 
vortexing. The formulation was sonicated with a probe-tip sonicator (Bandelin sonopuls HD 2070) at 
a power of 50 watt within a water bath at 55°C during 30 minutes. Then after, the suspension was 
cooled at RT, solution of HRP (unless other mentioned: 2 mg/mL in PBS 1x, 5 mL) was added into the 
formulation. The whole was frozen at a temperature of -80°C during at least 3 hours then freeze 
dried overnight (Kühler Freeze dryer ALPHA). Dried liposomes were rehydrated with phosphate-
buffered saline solution (PBS 1x, 0.5 mL) and vortexed until homogenization.  
 
Method 2 
Same method as Method 1, but instead of adding the enzyme after the sonication process, HRP was 
added into the freeze-dried powdered formulation. Dried liposomes as well as HRP were mixed 
manually with a spatula until a homogenous solution was obtained. Finally, the lyophilized product 
was rehydrated with PBS 1x (0.5 mL).  
Method 330 
One milliliter of chloroform solution of ready to use synthetic lipids (4mg/mL), C16 1,3-
diamidophospholipid, named Pad-PC-Pad,  was dried under reduced pressure, and left under high 
vacuum overnight. One milliliter of 5(6)- carboxyfluorescein-containing buffer [10 mM HEPES buffer, 
50 mM 5(6)-carboxyfluorescein dissolved in ultrapure water, pH 7.4 (NaOH), 200 mOsm (NaCl/L)] was 
added, and the film was hydrated within a water bath (65°C) for 30 minutes. Afterwards, five 
freeze/thaw cycles were preformed using liquid nitrogen and a 65 °C water bath. The suspension was 
extruded 11 times at 65°C using a miniextruder (Avanti Polar Lipids) and a track-etched filter 
membrane (pore size: 100 nm, Whatman). Finally, the liposomes were purified using a size exclusion 
chromatography (PD-10 desalting columns, GE Healthcare) and diluted to 50 mL with additional 
outer buffer (HEPES). The final suspension was left to rest at room temperature during 24 hours, in 
order to allow the formulation to reach equilibrium. 
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Another batch was formulated with exactly the same method but different liposome composition. 
Instead of Pad-PC-Pad, DPPC, DMPC and cholesterol (16.2 mg, 5.0 mg, 1.3 mg respectively in 1 mL 
HEPES buffer) was used.  
 
Method 4 
Given amounts of DPPC, DMPC and cholesterol (16.2 mg, 5.0 mg, 1.3 mg respectively) were dissolved 
in 1 ml chloroform. The solvent was removed under reduced pressure with a rotary evaporator at 
41°C. Then the given dried film was left under vacuum overnight. The thin lipid film was then 
hydrated with one milliliter PBS and left within a water bath at 45°C for more or less 24 hours until 
complete hydration of the thin film. The suspension was then extruded 11 times at 45°C using a 
miniextruder (Avanti Polar Lipids) and a track-etched filter membrane (pore size:100 nm, Whatman). 
Finally, liposomes were purified using size exclusion chromatography (PD-10 desalting column, GE-
Healthcare) and diluted to 50 mL with PBS 1x. 
 
3.3 Liposome’s size characterization 
Liposome size was determine by Dynamic light scattering (DLS) using a Malvern Instrument (Zen 
3600) connected to the Zetazizer software. The liposome’s formulation (from above) was diluted 103-
folds in PBS and 1 mL solution was analysed into a universal dip cell. The temperature of analysis was 
25°C and feature setting of 1.450 as for refractive index and 0.001 as for absorbance. 
3.4 Release measurement 
Measurement of HRP release 
For the measurement of HRP release, the formal formulation of liposome (from above) was first 
diluted 10-fold. Then two lots of seven aliquots of 100 μL diluted suspension were incubated for one 
hour at either room temperature or 37°C. In order to record a release trend, HRP quantification was 
measured at different time steps.  Before HRP quantification the formulation was centrifuged (8000 
g, 4 min) and the HRP concentration in the supernatant was measured using Amplex Red Kit. HRP 
was quantified in terms of units of enzymatic activity using a microplate reader (Wallac 1420 
Instrument) at 544 nm (excitation) and 590 nm (emission). The control 0% HRP delivery was 
determined at time zero whereas 100% delivery was set to an hour. 
Measurement of 5(6)-carboxyfluoroscein release 
Nine 1.5 mL aliquots of 5(6)-carboxyfluoroscein liposomal suspension were incubated at 37°C during 
a set amount of time. The release trend was recorded at different time steps (0, 5, 10, 15, 20, 30, 40, 
60 min), where 5(6)-carboxyfluorescein was quantified in triplicate using a fluorimeter (HIDEY Sense 
Microplate Reader) at 485 nm (excitation) and 535 nm (emission). The control 0% dye delivery was 
determine at time zero whereas 100 % dye delivery was determined by adding 2 vol % of a 10 vol % 
Triton-X100 to a sample.  
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RESULTS & DISCUSSION 
As a recall, the main aim of this study was to first develop thermoresponsive liposomes in order to 
develop an injectable HA-Tyr hydrogel. Indeed, such hydrogel would be a tremendous progress in 
regenerative medicine and in the tissue engineering domain. Ren et al. developed a process to 
trigger a crosslinking reaction with temperature sensitive vesicles resulting in a possible repair of 
joint micro-crack. In fact, despite the accurate protocols and explanations given by Ren et al., it was 
not as obvious as it seems to reproduce their experiment. Hereafter, is the chronological approach 
that was tried to replicate the Ren et al. research.   
At the beginning of the project, the liposome composition was chosen in order to target a phase 
transition temperature of 37°C. According to the Mabrey and Sturtevant study (Fig. 10, Section 2.1), 
the binary phase diagram of DPPC and DMPC gives a molar ratio of 3 for such a temperature. Hence, 
a ratio of 75% DPPC and 25% DMPC was chosen regarding the liposomal lipid composition. As for the 
addition of cholesterol, in most literature25 it is recommended to have 30% in mole of cholesterol 
within the composition. Actually, it helps to stabilize the lipid membrane as well as it prevents 
unwanted leakage. Several experiments were performed following the Method 1 in Section 3.2, until 
a first release trend was observed.  
4.1 First result 
First of all, the class of liposome has to be determined by calculating the vesicles size with dynamic 
light scattering (DLS). The graph below shows the size distribution expressed by a number 
(percentage) with regard to the particle diameter (nm). The measurements were taken in triplicate. 
 
Graph 1: Here the size distribution of the formulation prepared with method 1 is shown. This batch has the following 
composition: 80.9 mg DPPC, 25.2 mg DMPC, 29.4 mg cholesterol in 10 mL PBS, giving a lipid concentration of 10.5 mg/ml. 
The first two measurement are transposed on each other (green and red line), whereas the last 
measurement (blue line) shows larger vesicles. Nevertheless, this phenomenon is very common for 
liposome DLS measurement. Indeed, the suspension of liposomes is never completely homogeneous; 
hence variations in the measurement are often seen. The average size of this batch of liposome 
(mean size calculated with regard to each percentage) is 409 ± 49 𝑛𝑚. This value corresponds to the 
class of multi-lamellar vesicles MLV.  
The picture below allows the global visualization of this population of vesicles.  
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Figure 13: Liposome formulate with Method 1 in Section 3.2. The scale bar represent 100 μm. 
Despite that the vesicles are very small and that they are aggregated, Figure 13 shows clearly the size 
dispersion of MLV. From small vesicles to bigger ones, the population of liposome is dense and not 
homogeneous. However, it is this batch of liposome that gives the first HRP release. In Graph 2 is 
depicted the fluorescence with regards to a concentration expressed in terms of enzymatic activity. A 
sample of the formulation of liposome was left at 25°C and another sample at 37°C and the 
enzymatic activity of HRP in the supernatant of each sample was measured after one hour. In order 
to convert the fluorescent signal to a concentration, the HRP standard curve was also plotted.   
 
Graph 2: HRP release of two samples held for 60 min. at 25°C and 37°C. The blue dot line is the standard curve, the 
concentration in the supernatant is given by the orange point for the sample held at 25°C and the grey point for the sample 
held at 37°C. 
Graph 2 highlights the presence of a release when two samples of a common batch were held at 25°C 
and 37°C during one hour. In fact, the enzymatic activity of the sample left at 37°C is 4-fold higher 
than the sample left at room temperature.  
This experiment was performed once again in order to validate the model. Unfortunately, after 
several trials, this experiment was never reproducible. In order to understand the reason of these 
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discrepancies, every step of the formulation was investigated: such as the composition of the 
liposome, the release measurement method or the method of preparation.  
4.2 Composition optimization 
Since no release was observed at any other stage, the optimization of the composition of the 
liposome was begun. Perhaps the problem was due from the Tc of the bilayer being too loose (all 
HRP would have been released at 25°C, hence no release would be observed) or was too rigid 
(nothing could diffuse through the lipid membrane). Thus, formulations of different ratios of DPPC 
and DMPC with a constant amount of cholesterol (30% in mole) were formulated. Three different 
molar ratios were investigated: 1:1, 3:2 and 19:1 (DPPC and DMPC respectively). In fact, HRP release 
was not observed in any of these experiments. As the phase transition temperature of the vesicle is 
linked to the composition of the liposome, by decreasing the molar ratio DPPC/DMPC, Tc also 
decreases. Hence, it was expected that with lower amount of DPPC, with a same incubation 
temperature (37°C), HRP release would be easier. Subsequently, another experiment was performed 
but this time changing the concentrations of HRP with constant lipid composition: 2, 4 and 8 mg/mL 
were tried with lipid molar composition of approximately 53% DPPC, 17% DMPC and 30% 
cholesterol. The results made absolutely no sense either. Hence, HRP release was not observed 
under any of these conditions so one last experiment was performed using exactly the same 
liposome composition mentioned in the Ren et al. paper. Liposomes were formulated with 60 mg/mL 
lipid (DPPC, DMPC with a weight ratio of 2.3), having 5% by weight cholesterol. In terms of molar 
percentage, it gives a composition of 62% DPPC, 29% DMPC and 9% cholesterol. By significantly 
increasing the amount of lipids within the formulation (going from 10.5 mg/mL to 60 mg/mL) the 
encapsulation efficiency should have been increased. In addition, as the amount of cholesterol was 
lowered the membrane fluidity was increased. Unfortunately, once again no HRP release was 
observed. Consequently, as nothing worked as expected, the method of quantification of the release 
of HRP was investigated.  
4.3 Release method optimization 
As was mentioned before, two lots of liposomal suspension were incubated either at room 
temperature or at 37°C. At different time steps the concentration of HRP was measured. In order to 
eliminate the liposomes a step of centrifugation was performed before the quantification. One 
hypothesis was that the centrifugation step involves the loss of the liposome cargo. If the 
centrifugation speed is too rapid, liposomes can blow up due to centripetal force resulting in the 
release of the encapsulated material. This indeed would explain the reason why no release trend was 
observed. Hence, the speed and the time of the centrifugation step were changed from 8000 g to 
2000 g and from 4 minutes to 10 minutes. Unfortunately, the results were not any more 
encouraging. The second parameter that could be changed in the release method was the 
temperature of incubation. An additional experiment was run with an incubation temperature of 
45°C without any success. Finally, one last investigation was to make a close analysis of the method 
of formulation of Ren et al. 
4.4 Liposome formulation optimization 
The method of preparation of Ren et al. is depicted in the figure below. The first step consists of 
dispersion of the lipids and cholesterol into an organic solvent, in this case chloroform. The second 
step eliminates the chloroform using a rotary evaporator and proceeding to the third step where PBS 
is added on top of the thin film. During the hydration step, the temperature has to be higher than the 
phase transition temperature in order to allow the formation of vesicles. The formulation has to be 
left in a water bath during 30 minutes with intermittent vortexing. The fourth step is the sonication 
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step (also 30 minutes) in order to homogenize the population of vesicles and reduce their size. This 
step has to be at a temperature higher then Tc. Finally when the formulation reaches room 
temperature, dissolved HRP can be added to the suspension. The whole is frozen and dried and it is 
during the rehydration step that the HRP is encapsulated into the liposomes. 
 
Figure 14 : Ren et al. method for the formulation of liposome. 
The sensitive portion of this method is in the last step. HRP is added into the protocol in the fifth step 
and the encapsulation happens during rehydration. The first thing that was checked was whether 
HRP was denatured or not during the freeze and dry steps. It is well known that HRP is a very 
sensitive enzyme and can be easily deactivated. Two samples of a common solution were put at -
80°C and one of them was freeze-dried. The enzymatic activity was measured the day of the 
preparation of the solution and after being at -80°C and freeze-dried. The figure below shows the 
result of this experiment.  
 
Graph 3: Measurement of the enzymatic activity of HRP the day of preparation (Fresh) and the next day after being one 
night at -80°C and freeze-dried. 
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The enzymatic activity is related to the slope of the trend curves. The fresh preparation gives an 
enzymatic activity of 100% and has a slope of 66490 mL/mU. The enzymatic activity of the freeze (1) 
and freeze-dried (2) sample can be calculated as follow:  
(1) 
29484
66490
∙ 100 = 44.3% 
(2) 
26415
66490
∙ 100 = 39.7% 
The activity of the enzyme at -80°C lost 56% of its activity whereas for the freeze-dried process it lost 
60%. In conclusion, it seems to be the freeze step of process that deactivated the enzyme explaining 
the reason why the results are not relevant. Hence the Ren et al. method was changed as follows: 
 
Figure 15: Second method for the formulation of liposome (Method 2 in Section 2.3) 
Instead of adding HRP before the freeze-dried process, it was added at the end in its solid form. Dried 
liposome as well as HRP were mixed manually with a spatula. Then after the normal rehydration step 
another release experiment was performed but this time instead of keeping the samples at room 
temperature and 37°C, it was kept at 4°C and 37°C. This time a release was observed. 
4.5 Second results 
As usual when a release was observed a DLS measurement was performed. 
 
 
Graph 4: Here the size distribution of the formulation was prepared with the method 2 in Section 3.1. This batch has the 
following composition: 80.9 mg DPPC, 25.2 mg DMPC, 29.4 mg cholesterol in 10 mL PBS, giving a lipid concentration of 10.5 
mg/ml. 
The average size of this batch of liposome (mean size calculated in function of each percentage) 
is 1115 ± 157 𝑛𝑚 that is to say MLV vesicles were obtain once again. In comparison to the first 
release the liposomes are bigger and the solution is also not very homogeneous (3 different peaks). 
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The figure below depicts the liposome of this particular batch. Indeed the size of the liposomes are 
not homogeneous at all. Compared to the first batch prepared with Method 1 in Section 3.2 it seems 
that they are better dispersed. 
 
Figure 16 : Liposomes formulated with Method 2 in section 3.2. The scale bar represent 100 μm. 
In fact, adding HRP after the freeze-dried process gives larger liposome with high size distribution. 
This might come from the manual mixing which would induce a destabilization of the preformed 
liposomes. 
The release trend that was observed is showed in the graph below. 
 
Graph 5: Measurement of HRP release (method explain in Section 3.4). Instead of keeping the samples at 25°C and 37°C it 
was kept at 4°C and 37°C. The fluorescence of HRP in the supernatant (express in the y-axis) was measured at different time 
step: 0, 5, 20 and 60 minutes, where t0 is HRP activity at time zero. 
This result is quite surprising. In comparison to Ren et al. release measurement where most of the 
HRP was out the first 10 minutes, here it is after 60 minutes that the enzyme is out. 
Once again, this experiment was performed again without any success. 
4.6 Radu et al. encapsulation 
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In order to understand what could be wrong in the formulation of the liposome, Prof. Zumbühl from 
the University of Fribourg, was contacted in order to have some practical and technical advices. 
Luckily, his scientific team has elaborated liposomes that burst at exactly 37°C. Together with one of 
his assistant (Tanasescu R.), two batches of liposome were formulated using the artificial lipids and 
the binary mixture DPPC/DMPC. The method of preparation (Method 3, Section 3.2) was completely 
different from RDV’s method. Because Freeze-thaw cycles was used to hydrate the thin lipid it was 
not possible to encapsulate the enzyme. HRP would be completely deactivated. Carboxyfluoroscein 
was thus encapsulated. The release was successful with both liposome preparations.  
 
The Graph 6 represent the size distribution of the liposome formulation with Pad-PC-Pad lipids. 
 
Graph 6: DLS of the liposomes formulate with Method 3 in Section 3.2 with Pad-PC-Pad lipids. 
The average size of this batch cannot be calculate accurately. There is two peaks, one around 400 nm 
and another one around 1 micron. As the experiment was performed in the University of Fribourg, 
the DLS measurement was done only the day after the formulation of liposome. In consequence the 
liposomes probably form aggregate explaining the result of this DLS measurement.  
This was not the case for the liposome composed of DPPC and DMPC. Graph 7 depicts, three 
measurement that are well transpose on each other.  
 
 
Graph 7: DLS of the liposomes formulate with Method 3 in Section 3.2 with a binary mixture of DPPC and DMPC with 9% 
mol. cholesterol. 
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The average size of this batch of liposomes is 92 ± 25 𝑛𝑚 giving a population of Large Unimolecular 
Vesicles (LUV). Hence the extrusion process is better than sonication to reduce the size of the 
vesicles and give a homogeneous suspension. 
 
Two, almost, similar release trend were observed. In the graph below is depicted the release trend of 
carboxyfluoroscein through the lipid bilayer composed of DPPC, DMPC and 9% in mole cholesterol 
(orange trend) and through a membrane composed of the artificial phospholipids, named Pad-PC-
Pad (blue trend). 
 
 
Graph 8: The release trends of carboxyfluoroscein, through a lipid bilayer made of Pad-PC-Pad phospholipids (in orange) and 
through a bilayer made of a mixture of DPPC, DMPC and cholesterol bilayer (orange). 
 Both trends tends to release their cargo the first five minute. It seems that the liposome formulation 
with the binary mixture of DPPC and DMPC can encapsulate a higher amount of carboxyfluoroscein 
then the liposome formulate with the artificial lipids. 
4.7 Last experiment 
As the release of carboxyfluoroscein was a success a last experiment was tried. HRP was 
encapsulated using Tanasescu method and the freeze-thaw step was replace by a mild hydration of 
the thin film within a water bath of 45°C for 24 hours (Method 4, Section 3.2).   
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Graph 9: Measurement of the activity of HRP (express in fluorescence) at different time step: 0, 5, 10, 15, 20, 30 and 60 min. 
Method 4 in Section 3.2 was used to formulate this batch of liposome. 
Once again the results are unsatisfactory. The result give no relevant trend. 
4.8 Summery 
During this master project, it was unfortunately not possible to reproduce the Ren et al. experiment 
and the “trouble-shooting” experiments took much time and planning. Despite that the approach 
was well thought using the novel DRVs method to encapsulate a sensitive enzyme, several steps 
would still have to be improved in order to have reliable and reproducible results. 
Below are a few suggestions that were elaborated:  
First of all, as performed in Tanasescu’s method, after evaporation of the organic solvent with the 
rotary evaporator, the thin lipid film has to be put under vacuum overnight in order to get rid of any 
possible traces of solvent. Indeed, remaining solvent during the hydration steps can inhibit the 
formation of vesicles or deteriorate the formulation equilibrium. It was observed that evaporation of 
the solvent with rotary evaporator was never reproducible from one batch to another within the 
same conditions and traces of solvent were almost always perceived before hydration. 
Second, as mentioned in the “Liposome’s formulation” chapter, the use of a probe tip sonicator is 
not advised. One the one hand, the solution can be polluted with probable metallic residue and on 
the other hand the encapsulation efficiency is pretty low. To ensure at least no metallic 
contamination, the Ren et al. method has to introduce a centrifugation step before the addition of 
the enzyme. Another point that was observed during the sonication process was that temperature 
control of the formulation was complicated if not impossible. Due to the high ultrasonic frequency, 
part of this energy was converted into heat resulting on a temperature increase within the 5 mL 
batch. Thus, unavoidable evaporation of part of the water, causing non-negligible volume reduction, 
was occurring. Consequently, most of the time additional PBS was added during the process, 
implying thermodynamic equilibrium loss.  In sum, the probe tip sonicator step is arbitrary and does 
not ensure reproducible results. A solution to this problem would be to replace the sonication step 
by an extrusion step. Indeed, during extrusion temperature can be well monitored as well as the size 
of the particles. It gives a more homogeneous formulation and is more reproducible. 
Finally, the last suggestion is to completely change the method of formulation of liposome and take 
Tanasescu’s method. The results demonstrated that encapsulation of carbofluoresceine was a 
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success and a release occurred at 37°C. This means that the composition of the liposomes as well as 
the 9 % mol. of cholesterol gives effective liposomes. 
. 
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PERSPECTIVE 
All along this project, there have been unexpected events as well as pleasant surprises: from many 
liposome formulation defeats to success by working with grand artificial phospholipids. If the aim of 
this project was to develop thermoresponsive liposome with a release target temperature of 37°C, 
then the goal would have been achieved. Two types of thermoresponsive liposomes were developed 
within this study, the one of Ren et al. and the alternative Tanasescu et al. method. For both of them, 
the carboxyfluoroscein’s release occurs at exactly 37°C. Nonetheless, HRP encapsulation and 
monitoring the release rate were key factors for the development of an injectable HA-Tyr hydrogel. 
Therefore, in order to complete this mission, there are still remaining research experiments to be 
accomplished. 
Since two different kinds of liposome were developed, here are already two options to continue this 
study. 
If the desire would be to further develop the encapsulation of HRP within liposome made of DPPC 
and DMPC, then here are several steps that could be done. First, for the reasons mentioned in the 
5.6 Section the preparation method should be revised in order to have a reproducible and stable 
formulation. Reproducible formulations are key factors for the control of the release rate, especially 
when it is intended to launch a crosslinking reaction. Multi-lamellar vesicles are hardly stable and to 
reproduce the encapsulation efficiency of MLV is quasi impossible. Hence, the Method 4 in the 
“Materials and Methods” chapter should be used. Indeed, this method enables the formation of LUV 
with low size distribution. The stability of the liposome would, thus be improved compared to MVL. 
Furthermore, this method uses milder conditions (𝑇 ≤ 45°𝐶), monitors well the temperature and 
gives opportunity to work with lower volume (0.5 to 1 mL). Having the opportunity to work with 
lower volume enables one to increase the amount of lipids in a batch. Thus, investigation of 
encapsulation efficiency with regard to the amount of lipids could be achieved. As the amount of 
lipids is anyway lower than for a 10 mL batch, more experiments could be done for a same overall 
cost.  It is obvious that before anything, it should be examined that HRP can withstand the shear 
stress implied by the extrusion step. This can easily be performed by quantifying the activity of HRP 
before and after extrusion. If the activity remains the same then HRP does not lose any of its activity 
during the process. If it happens that shear stress denatures the enzyme, hence another method to 
convert MLV into LUV should be found. Finally, one last point that should be mentioned here, is 
before starting all the process to record a potential release trend, it should first be proved that HRP is 
well encapsulated. It is well known that detergent such as Triton X-100 or SDS can solubilize lipid 
membranes. However, these surfactants are so strong that they might denature the enzyme, 
resulting on an enzymatic activity loss. A suggestion given by Tanasescu’s colleague was to burst 
liposome by inducing an osmotic gradient between the inner and outer side of the vesicles. Indeed 
PBS has an osmolarity of 214 mOs, whereas ultrapure water has an osmolarity of zero. The liposome 
formulation should be done using PBS as usual and in order to check whether HRP has been 
encapsulated or not, a dilution should be done using on one side PBS and on the other side ultrapure 
water. A quantification of both solutions will answer the question whether HRP was encapsulated or 
not.   
On the second hand, if the desire would be to further work with artificial phospholipids (1,3-
diaminophospholipid, named Pad-PC-Pad) developed by Prof. Zumbühl and his team, then this is 
another issue. Indeed, these artificial phospholipids seem very promising, giving a novel kind of 
liposome being thermo- as well as mechano-sensitive. This feature has great potential for the 
development of any kind of inducible system. Further studies should be performed in order to 
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encapsulate HRP within their artificial membranes, not forgetting that a collaboration/partnership is 
necessary as their phospholipids are not on the market yet. 
The last point to highlight to assure the project continuation is to perhaps change the HRP 
quantification technique. Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit is a very sensitive 
method to detect peroxide. Nonetheless, it might be too sensitive. A high dilution is required (in the 
order of 106-folds) which may create additional potential errors as well as very small impurities which 
could in turn alter the signal. 
In conclusion, to develop a thermoresponsive system for HRP delivery aiming to trigger and control 
HA-Tyr crosslinking reaction, further research is indeed of merit. The overall goal of this project was 
quite challenging. However, to improve joint healing by finding a way to formulate an injectable 
thermolabile hydrogel would be a major step forward.  
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ANNEX 
A: Supplementary figures 
 A1 - Properties of mainly used phospholipids22 
Lipids Abbreviation 
Carbons : 
Saturations 
Charge at 
pH 7.4 
Tc (°C) 
Neutral natural lipids     
Egg phosphatidylcholine EPC  0 -15 to -7 
Soy phosphatidylcholine SPC  0 -15 to -7 
Neutral synthetic lipids     
Dilauryloyl pholsphatidylcholine DLPC 12 :0 0 -1 
Dimyristoyl pholsphatidylcholine DMPC 14 :0 0 23 
Dipalmitoyl pholsphatidylcholine DPPC 16 :0 0 41 
Distearoyl pholsphatidylcholine DSPC 18 :0 0 55 
Dioleoyl pholsphatidylcholine DOPC 18 :1 0 -20 
Dimyristoyl pholsphatidylethanolamine DMPE 14 :0 0 50 
Dipalmitoyl pholsphatidylethanolamine DPPE 16 :0 0 63 
Distearoyl pholsphatidylethanolamine DSPE 18 :0 0 74 
Dioleoyl pholsphatidylethanolamine DOPE 18 :1 0 -16 
Negatively charged synthetic lipids     
Dilauryloyl phosphatidylglycerol DLPG 12 :0 -1 4 
Dimyristoyl phosphatidylglycerol DMPG 14 :0 -1 23 
Dipalmitoyl phosphatidylglycerol DPPG 16 :0 -1 41 
Distearoyl phosphatidylglycerol DSPG 18 :0 -1 55 
Dioleoyl phosphatidylglycerol DOPG 18 :1 -1 -18 
Dimyristoyl phosphatidic acid, pH 6 DMPA 14 :0 -1 51 
Dimyristoyl phosphatidic acid, pH 9 DMPA 14 :0 -2 45 
Dipalmitoyl phosphatidic acid, pH 6 DPPA 16 :0 -1 67 
Dipalmitoyl phosphatidic acid, pH 9 DPPA 16 :0 -2 58 
Dipalmitoyl phosphatidylserine DPPS 16 :0 -1 51 
Positively charged synthetic lipids     
Stearylamine SA 18 :0 +1 - 
di-Oleoylosytrimethylamoniopropane DOTAP 18 :1 +1 - 
Table 1: Main phospholipids used for the formulation of liposomes. 
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 A2 - Newman conformations of butane31 
Rotation around the central C2-C3 bond in butane involves conformers of different energies: 
 
Figure 17: Newman projection of butane  
Conformation from left to right: eclipsed, gauche, eclipsed, anti, eclipsed, gauche, eclipsed 
 
The most stable isomer is the anti-conformation (dihedral angel of 180°). As the methyl groups are 
on both sides of the C2-C3 bond the steric repulsion are the smallest. Hence, the anti-conformation is 
referred as the zero energy all conformers. Eclipsed isomers (with the highest energy), have greater 
steric repulsion than gauche isomer therefore the eclipsed isomers are higher in energy then the 
gauche conformations.  
 
